EDGE
Get a demo
Log In
All Updates

All Updates

icon
Filter
Product updates
Genialis and PanCAN partner to advance KRAS diagnostics in pancreatic cancer
Precision Medicine
May 31, 2024
This week:
Product updates
Stability AI launches Stable Diffusion 3 Medium, a text-to-image model
Foundation Models
Yesterday
Product updates
Microsoft discontinues GPT Builder in Copilot
Generative AI Applications
Yesterday
Funding
BlinqIO raises USD 5 million in funding to expand operations
Generative AI Applications
Yesterday
Product updates
Databricks launches innovations to Mosaic AI for production-quality applications
Generative AI Infrastructure
Yesterday
M&A
Rebellions and Sapeon Korea merge to challenge global AI chip leader
Generative AI Infrastructure
Yesterday
M&A
Pluxee to acquire Cobee; expands employee benefits offering
Remote Work Infrastructure
Yesterday
Product updates
Space and Time launches 'Proof of SQL' solution on GitHub
Enterprise Blockchain Solutions
Yesterday
Partnerships
Lido partners with Mellow Finance to launch liquid restaking vaults
Decentralized Finance (DeFi)
Yesterday
Funding
Rivia raises EUR 3 million in seed funding
Clinical Trial Technology
Yesterday
Partnerships
Product updates
Databricks and Shutterstock collaborate to launch enterprise-optimized ImageAI model
Generative AI Infrastructure
Yesterday
Precision Medicine

Precision Medicine

May 31, 2024

Genialis and PanCAN partner to advance KRAS diagnostics in pancreatic cancer

Product updates

  • Genialis has partnered with the Pancreatic Cancer Action Network (PanCAN) to extend the validation of Genialis' krasID biomarker in pancreatic cancer histology, an AI classifier that predicts response and clinical benefit to KRAS inhibitors across preclinical, clinical, and real-world settings.

  • The partnership aims to use the Genialis krasID, an AI-powered tool capable of forecasting the response to KRAS inhibitors in various settings. The collaboration is set to advance Genialis krasID as a diagnostic tool to assist in developing new medicines and help doctors plan treatment for pancreatic cancer.

  • It is also expected to expedite the development of KRAS-targeted therapies to improve treatment outcomes for patients with pancreatic cancer.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.